ADAPTIVE BIOTECHNOLOGIES (ADPT)       8.44  +0.2 (+2.43%)

8.44  +0.2 (+2.43%)

US00650F1093 - Common Stock - After market: 8.44 0 (0%)

ADAPTIVE BIOTECHNOLOGIES8.44

NASDAQ:ADPT (3/29/2023, 7:00:00 PM)+0.2 (+2.43%)

After market: 8.44 0 (0%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryLife Sciences Tools & Services
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)02-14 2023-02-14/amc
Earnings (Next)05-02 2023-05-02/amc
Ins Owners3.51%
Inst Owners93.01%
Market Cap1.21B
Shares143.23M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts80
IPO06-27 2019-06-27

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ADPT Daily chart

Company Profile

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. The company is headquartered in Seattle, Washington and currently employs 790 full-time employees. The company went IPO on 2019-06-27. The firm is focused on using the biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine (IM) platform combines a suite of chemistry, computational biology and machine learning to generate clinical immunomics data to decode the adaptive immune system. Its clinical diagnostic product, clonoSEQ, is used for the detection and monitoring minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL). The IM business consists of two areas: IM Pharma Services and Drug Discovery. Its immunoSEQ utilizes bias-controlled polymerase chain reaction (PCR) to sequence immune receptors from deoxyribonucleic (DNA).

Company Info

ADAPTIVE BIOTECHNOLOGIES

1165 Eastlake Ave E

Seattle WASHINGTON 98102

P: 12066590067.0

CEO: Chad Robins

Employees: 790

Website: https://www.adaptivebiotech.com

ADPT News

News Image3 days ago - Market News VideoAdaptive Biotechnologies (ADPT) Shares Cross Above 200 DMANews Image8 days ago - ChartmillWhat's going on in today's after hours session

Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.

News Image8 days ago - Seeking Alpha(NASDAQ:ADPT)

Gainers: Maxpro Capital Acquisition  (JMAC) +31%. Telesis Bio (TBIO) +10%

News Imagea month ago - Adaptive BiotechnologiesAdaptive Biotechnologies to Participate in the 43rd Annual Cowen Healthcare ConferenceNews Imagea month ago - Adaptive BiotechnologiesAdaptive Biotechnologies to Participate in the 43rd Annual Cowen Healthcare Conference

SEATTLE, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage...

News Imagea month ago - Market News VideoAdaptive Biotechnologies (ADPT) Shares Cross Below 200 DMA

ADPT Twits

Here you can normally see the latest stock twits on ADPT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example